NCT04540627View on ClinicalTrials.gov

Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

July 6, 2020

Primary Completion Date

October 23, 2020

Study Completion Date

October 23, 2020

Conditions
Healthy Adult Participants
Interventions
DRUG

Palivizumab

Liquid solution in sterile water for injection (final concentration of 20mg/mL), intravenous infusion, single dose of 8mg/kg or 15mg/kg, administered at a rate of 1mL/min

DRUG

Placebo

Sodium Chloride 0.9% Solution (Normal Saline), intravenous infusion, single dose of 0mg/Kg, administered at a rate of 1mL/min

OTHER

RSV-A Memphis 37b virus

Single Intranasal Virus Dose (challenge dose is approximately 4.5log10 PFU)

Trial Locations (1)

E1 2AX

hVIVO Services Limited, London

All Listed Sponsors
lead

mAbxience Research S.L.

INDUSTRY

NCT04540627 - Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV | Biotech Hunter | Biotech Hunter